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Insulin-like growth factor 1 (IGF1) induces skeletal
muscle hypertrophy by activating the IGF1R/IRS1/
PI3K/Akt pathway. However the effect of IGF1 in
differentiated muscle is limited by IRS1 ubiq-
uitination and proteasome-mediated breakdown. In
skeletal muscle, IGF1R activation sensitizes IRS1 to
degradation, and a screen for the responsible E3
ligase identified Fbxo40 as mediating this rapid
turnover of IRS1, since IRS1 loss can be rescued by
knockdown of Fbxo40. In biochemical assays, an
SCF E3 ligase complex containing Fbxo40 directly
ubiquitinates IRS1, and this activity is enhanced by
increased tyrosine phosphorylation of IRS1. Fbxo40
is muscle specific in expression and is upregulated
during differentiation. Knockdown of Fbxo40
induces dramatic hypertrophy of myofibers. Mice
null for Fbxo40 have increased levels of IRS1 and
demonstrate enhanced body and muscle size during
the growth phase associated with elevated IGF1
levels. These findings establish an important means
of restraining IGF1’s effects on skeletal muscle.
INTRODUCTION
The IGF1/IRS1/PI3K/Akt pathway induces skeletal muscle
hypertrophy, both by increasing protein synthesis (Coleman
et al., 1995; Lai et al., 2004; Musaro` et al., 2001; Pallafacchina
et al., 2002; Rommel et al., 2001; Izumiya et al., 2008), and by
blocking protein degradation (Sandri et al., 2004; Stitt et al.,
2004). IGF1 modulation of protein synthesis downstream of
IRS1/Akt operates in part by activating mammalian target of
rapamycin (mTOR) signaling (Glass, 2005a; Le´ger et al., 2006;
McGee et al., 2008; Mounier et al., 2009; Park et al., 2005); its
inhibition of protein degradation is via IRS1/Akt-mediated
inhibition of the Forkhead, or Foxo, family of transcription factors
(Sandri et al., 2004; Stitt et al., 2004), which are required for the
upregulation of the E3 ubiquitin ligases MuRF1 and MAFbx,
which are, in turn, required for skeletal muscle atrophy (Bodine
et al., 2001; Glass, 2005b, 2010).
The IGF1 pathway can be inactivated by targeting IRS1 for
ubiquitin-mediated degradation. This has been reported in
settings of prolonged insulin-mediated cell stimulation, in whichDevelopmeIRS1 was degraded in a PI3K-sensitive fashion, in various cell
lines (Haruta et al., 2000; Lee et al., 2000; Tzatsos and Kandror,
2006; Xu et al., 2008; Zhande et al., 2002). However, these
reports differ in terms of the pathways downstream of PI3K
that modulate IRS1 turnover (Haruta et al., 2000; Tzatsos and
Kandror, 2006; Xu et al., 2008; Zhande et al., 2002). Some
suggest that the PI3K/Akt/mTOR pathway activates IRS1 degra-
dation in MCF-7 (Xu et al., 2008) and 293 cells (Tzatsos and
Kandror, 2006), while other reports suggest that activation of
PI3K but not mTOR signaling is required for IRS1 degradation
(Zhande et al., 2002).
Several distinct E3 ubiquitin ligases have been demonstrated
to serve as IRS1 ligases, including SOCS1 and SOCS3, which
were shown to promote degradation of IRS1 and IRS2, and
which may mediate inflammation-induced insulin resistance
(Rui et al., 2002). Cbl-b was reported to degrade IRS1 in settings
of muscle atrophy (Nakao et al., 2009). The cullin 7 complex,
containing the E3 ligase Fbxw8, was shown to be activated by
anmTOR-dependent negative feedback loop after which it could
degrade IRS1 (Xu et al., 2008).
In this study, we demonstrate that the E3 ubiquitin ligase
Fbxo40 induces IRS1 ubiquitination and breakdown specifically
in skeletal muscle cells and only upon IGF1 stimulation, thus
identifying a regulator of IGF1-induced skeletal muscle signaling.RESULTS
IRS1 Is Rapidly Degraded in Skeletal Myotubes
Because IGF1 has been demonstrated to be sufficient to induce
hypertrophy in adult skeletal muscle, we were interested to know
whether IRS1 is degraded upon IGF1 treatment of differentiated
muscle cells, or myotubes, since this could limit the utility of IGF1
as an anabolic agent. We also checked IRS1 stability during an
atrophy stimulus—after treatment with the glucocorticoid
dexamethasone (DEX)—to determine whether settings in which
protein breakdown was enhanced would affect IRS1 stability.
To discriminate between degradation of IRS1 and its synthesis,
a protein synthesis inhibitor, emetin (Eme), was used to
determine the degradation rate of IRS1. Differentiated C2C12
myotubes were treated with increasing concentrations of IGF1
or DEX, plus or minus Eme. In C2C12 myotubes, IRS1 is
degraded upon IGF1 but not DEX treatment, in a dose-depen-
dent manner (see Figure S1A available online). In contrast, the
upstream signaling molecule, the insulin-like growth factor 1
receptor (IGF1R), is not affected by either treatment. Based on
these data, we chose 10 nM IGF1 for our further experiments,ntal Cell 21, 835–847, November 15, 2011 ª2011 Elsevier Inc. 835
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Figure 1. Stability of IRS1 in C2C12 Myotubes
(A) Stability of IRS1 was measured in C2C12 myotubes. Total cell lysate (20 mg) was analyzed by western blotting.
(B) C2C12 myotubes were infected 2 days postdifferentiation with adenovirus expressing his-myc-ubiquitin. Forty-eight hours after infection, myotubes were
treated with IGF1 (10 nM) alone, IGF1 withMG132 (20 mM), IGF1 with G5 (5 mM), or IGF1 with MG132 andG5 for 5 hr. Cell lysates (1 mg) were immunoprecipitated
with 3 mg of anti-IRS1 rabbit polyclonal antibody or nonspecific IgG. An aliquot (20 mg) of the lysate along with 100% of the eluate were analyzed by western
blotting with antibodies against myc (detecting his-myc-ubiquitin, top panel) or IRS1 (bottom panel). The molecular weight (Mw) of protein ladder (kDa) is
indicated on the right. *Cross-reacted IgG heavy chain.
(C) C2C12myotubes were infected 2 days postdifferentiation with adenovirus expressing his-myc-ubiquitin. Forty-eight hours after infection, the myotubes were
treated for 5 hr with the following: (1) MG132 (20 mM); (2) IGF1 (10 nM) and MG132; (3) G5 (5 mM); (4) IGF1 and G5. Cell lysate (800 mg) was subjected to
immunoprecipitation with anti-IRS1 polyclonal antibody. The eluate was analyzed by western blotting with anti-IRS1 polyclonal antibody (left panel). The right
panels show total cell lysate (20 mg) blotted with antibodies against myc (detecting his-myc-ubiquitin) and tubulin (as loading control). Mw of protein ladder in kDa
is indicated on the right.
See also Figure S1 and S2.
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Fbxo40 Induces IRS1 Ubiquitination in Musclesince 10 nM was sufficient to induce the effect. In C2C12
myotubes, IRS1 is rapidly degraded upon IGF1 treatment, with
a half-life of around 2 hr (Figure 1A). Note that in Figure S1B,
IRS1 protein levels also decreased in cells treated with IGF1
alone, without Eme added, though with slower kinetics, suggest-
ing that its rapid degradation outstrips active protein synthesis
upon IGF1 stimulation.
IRS1 is degraded through a proteasome-dependent pathway,
based on the observation that the proteasome inhibitor MG132
substantially stabilizes IRS1 in the setting of IGF1 stimulation
(Figure 1A). In order to determine whether ubiquitinated IRS1
protein could be detected after IGF1 stimulation, C2C12 myo-
tubes were infected with an adenovirus overexpressing his-
myc tagged ubiquitin, and then these myotubes were incubated836 Developmental Cell 21, 835–847, November 15, 2011 ª2011 Elswith IGF1 along with either MG132 or the isopeptidase inhibitor
G5 (to block deubiquitination and thus increase the ability to
capture the ubiquitinated species) (Figure 1B). IRS1 was immu-
noprecipitated with an anti-IRS1 antibody (Figure 1B, lanes 6,
8, 10, 12) or a rabbit IgG as a negative control (Figure 1B, lanes
5, 7, 9, 11). Polyubiquitination was detected with a monoclonal
anti-myc antibody against his-myc tagged ubiquitin and was
found to be specifically immunoprecipitated with IRS1 (Fig-
ure 1B, upper panel). Visualization of the polyubiquitinated
IRS1 is more clearly seen with G5 treatment (Figure 1B, lower
panel, lanes 10 and 12), demonstrating that deubiquitinating
enzymes are active in the myotubes, and thus need to be
inhibited in order to stabilize ubiquitin conjugates of IRS1. In
agreement with the induced degradation of IRS1 upon IGF1evier Inc.
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Fbxo40 Induces IRS1 Ubiquitination in Muscletreatment, polyubiquitinated IRS1 increased upon IGF1 treat-
ment (Figure 1C, left panel), while total ubiquitinated proteins
actually decreased slightly (Figure 1C, right panels), as might
be expected given IGF1’s antiatrophy effects (Glass, 2010).
Blocking the degradation of IRS1 by MG132 rescues Akt/
p70S6K signaling (Figure 1A; Figure S1C). Surprisingly, this rapid
degradation of IRS1 in myotubes cannot be rescued using PI3K,
Akt, mTOR, MEK1/2, GSK3, p38, or JNK inhibitors (Figure S1C
and data not shown), implying that IRS1 turnover in this setting
is regulated simply by IGF1/IGF1R-mediated phosphorylation
of IRS1. This finding distinguishes the IRS1 degradation seen
in the setting of IGF1 stimulation from previous reports of IRS1
turnover.
We also examined IRS1 degradation in undifferentiated
C2C12 myoblasts. While IRS1 is again degraded upon IGF1
treatment in a dose-dependent manner, the half-life of IRS1 in
C2C12 myoblasts is significantly prolonged in comparison to
that observed in myotubes—around 6 hours in a myoblast
versus 2 hours in a myotube (Figure S2A versus Figure 1A).
Note that in Figure S2B, without protein synthesis inhibitor,
IRS1 protein level does not decrease with IGF1 treatment, in
contrast to the case in myotubes (Figure S1B), due to active
protein synthesis and slower protein degradation in the
myoblasts. In contrast to what was observed in a differentiated
myotube, inhibitors of PI3K can rescue IRS1 degradation in
a myoblast setting (Figures S2C and S2D), adding to the impres-
sion that the degradation process seen in a myotube is a distinct
and stage-specific mechanism of IRS1 regulation in skeletal
muscle. This finding was later explained by the demonstration
that Fbxo40 expression is differentiation specific.
IRS1 Is Targeted by the Skp1-cullin 1-Rbx1 Complex
Next, we determined the E3 ligase that is responsible for target-
ing IRS1 to the proteasome for degradation upon IGF1 stimula-
tion. Since IRS1 is degraded rapidly in C2C12 myotubes, and is
distinctly regulated in comparison to that seen in C2C12
myoblasts (and other cell types reported so far in the literature),
we focused our search for responsible E3s on C2C12 myotubes,
reasoning that even if the E3 was one of those previously re-
ported, it would be necessary to see if its regulation was distinct
in the setting of differentiated muscle cells. Thus, we started with
reported E3s that regulate IRS1 in fibroblast type cell lines, to
determine whether they are required for the loss of IRS1 seen
in myotubes; cullin 7-Fbxw8 complex (Xu et al., 2008) (Figures
S3A–S3D) and Cbl family members (Suzue et al., 2006; Nakao
et al., 2009) (Figures S3F and S3G) were examined, and
scrambled control siRNA (siCON) was included as control.
Neither of these was found to be responsible for the rapid
degradation of IRS1 in myotubes. We also checked the
elongin B/C protein complex since it was reported that SOCS1
and SOCS3 may regulate IRS1 overexpressed in 293 cells
(Rui et al., 2002). There was no significant rescue of IRS1 degra-
dation demonstrated when elongin B mRNA was decreased to
20% of basa level (data not shown). In addition, a distinct E3
ligase, Nedd4, has been suggested to regulate ligand-induced
degradation of IGF1R (Vecchione et al., 2003), but its
knockdown failed to demonstrate a requirement in the IGF1-
induced IRS1 degradation observed in C2C12 myotubes (data
not shown).DevelopmeThere are more than 600 E3 ligases in the mammalian cell (Li
et al., 2008), which include two large protein families, the
RING-finger domain (RNF) and HECT domain containing E3
ligases. RNF-dependent E3 ligases can be further divided into
two categories: the single polypeptide chain RNF E3s and the
multisubunit cullin-RING E3 complexes. Within this latter cate-
gory, there are four different classes; each consists of a RING
protein (Rbx1), one of seven different cullin family members
and various adaptor proteins. This information allows one to
narrow the potential E3 class involved by knocking down
Rbx1, since its involvement would point to the Rbx1/cullin-
required families of E3s. C2C12 myotubes were therefore trans-
fected with three different siRNAs targeting Rbx1. siRbx1_1 and
siRbx1_2 decreased Rbx1 protein to 50%of basal levels, and yet
even with this modest knockdown an almost 100% blockade of
IGF1-induced IRS1 degradation was observed; as a control,
siRbx1_3, which does not knock down protein significantly,
had no effect (Figure 2A). This result narrowed our search to
the multisubunit cullin-Ring E3 complexes. We next differenti-
ated the four subtypes, using siRNAs to different cullin family
members and adaptor proteins. Knockdown of Skp1 (Figure 2B)
and cullin 1 (Figures 2C and 2D) resulted in reduced loss of IRS1,
suggesting that the Rbx1 containing Skp1-cullin 1-F-box (SCF)
complex comprises the subfamily of E3 ligases targeting IRS1
for proteasomal degradation. As a control, cullin 2-containing
cullin-Ring E3 complexes were tested and determined to be
not required (Figures S4A and S4B). Of note, Rbx1 can be coim-
munoprecipitated with IRS1, demonstrating that these two
proteins exist in a complex (Figure 2E). This finding allowed us
to focus on genes encoding F-box containing proteins as the
likely source of the E3s in this case.
Fbxo40 Associates with Skp1-cullin 1-Rbx1
and Targets IRS1 for Degradation
Seventy-seven F-box proteins have been identified so far in
mice. We used a functional genomic approach to screen 68 of
these F-box containing proteins to determine if any could target
IRS1 for degradation (siRNAs to the remaining genes were not
represented in the library). C2C12 myotubes were transfected
with a mouse ubiquitin conjugation siRNA library from Dharma-
con (subset 2), which contains siRNAs against SOCS-box and
F-box containing proteins. Two days posttransfection, myo-
tubes were treated with 10 nM IGF1 for 16 hr, and IRS1 protein
level was analyzed by western blotting. The positive hits from
this screen were further corroborated by three different siRNAs
to the F-box gene under study, obtained from a different source,
QIAGEN. Knockdown efficiency was evaluated by quantitative
real-time PCR (qRT-PCR) for the positive hits. The results of
the screen are summarized in Table 1. Of the 68 genes encoding
F-box proteins screened, we identified one positive hit, Fbxo40.
Figure 3A demonstrates the dose-dependent rescue of IRS1
achieved by knocking down Fbxo40. Among the three siRNAs
targeting Fbxo40, siFbxo40_7 decreases the protein level to
10% of basal level and has the best efficacy, while siFbxo40_9,
which leads to the least effective knockdown, only caused a
small increase of IRS1 protein above control level (Figure 3A,
left panels). Importantly, none of these three siRNAs caused an
increase in IRS1 protein level without IGF1 treatment (Figure 3A,
right panels), indicating phosphorylation of IRS1 downstream ofntal Cell 21, 835–847, November 15, 2011 ª2011 Elsevier Inc. 837
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Figure 2. An SCF Family Member E3 Ligase Targets IRS1 in C2C12 Myotubes
(A–C) C2C12 cells were transfected with three individual siRNAs each to Rbx1 (A), Skp1 (B), and cullin1 (C) or siCON 1 day postdifferentiation. Forty-eight hours
after transfection, cells were starved and treated with IGF1 or IGF1 plus MG132 for 16 hr. Cell lysate was analyzed by western blotting.
(D) C2C12 cells were transfected with three individual siRNAs to cullin 1 or siCON 1 day postdifferentiation. Forty-eight hours after transfection, RNA was
harvested and analyzed by qRT-PCR. ThemRNA level of b-actin was used as internal control to normalize the RNA amount added. Themean fold change (versus
siCON transfected cells) ± SEM of three independent samples is plotted. This is representative of three replicate experiments. *p < 0.0001 versus control sample
by one-way ANOVA and Bonferroni post test, n = 3.
(E) Day 3 C2C12myotubes were starved and treated with IGF1 andMG132 for 16 hr. Cell lysate (1 mg) was immunoprecipitated with 3 mg of anti-IRS1 antibody or
nonspecific IgG and sheep anti-rabbit IgG Dynabeads. The eluate was analyzed by western blotting.
See also Figure S3 and Figure S4.
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Fbxo40 Induces IRS1 Ubiquitination in MuscleIGF1R activation is required for Fbxo40 targeting of IRS1 for
degradation. In C2C12 myotubes with knockdown of Fbxo40,
the half-life of IRS1 increased to more than 6 hr (Figure 3B),
similar to what has been observed in C2C12 myoblasts
(Figure S2A). Interestingly, in siFbxo40 transfected cells, phos-
phorylation of Akt on both S473 and T308 sites was maintained
after 4 hr of IGF1 stimulation, demonstrating that sparing of IRS1
can lead to preservation of downstream signaling through
Akt (Figure 3B). Furthermore, knockdown of Fbxo40 leads to
the rescue of IRS1 upon either of two different doses of IGF1
stimulation (Figure 3C).
We surveyed the FirstChoice Human Total RNA Panel
(Ambion) by qRT-PCR and found that Fbxo40 is almost exclu-
sively expressed in heart and muscle, demonstrating that it is
muscle specific (Figure S5A). Furthermore its mRNA is induced
during differentiation of C2C12 cells (Figure S5B), explaining
why the rapid degradation of IRS1 upon IGF1 stimulation is
only observed in differentiated myotubes. Consistent with the
mRNA expression data, Fbxo40 protein can only be detected
in the 1%NP-40 soluble fractions of C2C12 cell lysates 3 days
after differentiation (Figure 3D).
IRS1 and the eachmember of the SCF complex (Skp1, cullin 1,
and Rbx1) can be coimmunoprecipitated with Fbxo40 (Fig-838 Developmental Cell 21, 835–847, November 15, 2011 ª2011 Elsure 4A). We also used this immunoprecipitated SCFFbxo40
complex to ubiquitinate recombinant N-terminal His6 tagged
IRS1 in vitro. This insect-cell produced His6-IRS1 contains low
level of tyrosine phosphorylation (Figure 4C) and can be ubiqui-
tinated in a time-dependent manner (Figure 4B). In this experi-
ment, we included six control reactions. The first four controls
are reactions carried out at 30C for 90 min with the omission
of E1, or E2 (UbcH5c), or Biotin-N-terminal ubiquitin, or recombi-
nant His6-IRS1, respectively. The last two controls are full
reactions carried out without immunoprecipitated Fbxo40 (with
beads incubated with lysate without IgG or with nonspecific
rabbit IgG). The bottom panel shows total ubiquitinated proteins
detected by streptavidin-HRP; the middle panel shows Fbxo40
eluted from beads. We also subjected a duplicate set of the
reaction to immunoprecipitation by a polyclonal antibody against
IRS1. Eluate from the beads was immunoblotted with streptavi-
din-HRP to detect polyubiquitinated IRS1 (Figure 4B, top panel).
Polyubiquitinated IRS1 can be observed in full reactions after 60
or 90 min at 30C. This recombinant His6-IRS1 can be further
in vitro phosphorylated by GST tagged soluble IGF1R kinase
domain (GST-IGF1RKD) in a time-dependent manner (Baer
et al., 2001) (Figure 4C). In order to determine whether extensive
tyrosine phosphorylation of IRS1, which happens in cells afterevier Inc.
Table 1. Summary of F-Box Proteins Screening Result
F-Box
Protein
In the
Library?
Rescue
IRS1?
F-Box
Protein
In the
Library?
Rescue
IRS1?
F-Box
Protein
In the
Library?
Rescue
IRS1?
F-Box
Protein
In the
Library?
Rescue
IRS1?
Fbxw1a +  Fbxl1 +  Fbxo1 +  Fbxo25 + 
Fbxw2 +  Fbxl2 +  Fbxo2 +  Fbxo27 + 
Fbxw4 +  Fbxl3 +  Fbxo3 +  Fbxo28a + 
Fbxw5a +  Fbxl4a +  Fbxo4 +  Fbxo30a + 
Fbxw7a +  Fbxl5 +  Fbxo5 +  Fbxo31 + 
Fbxw8a +  Fbxl6 +  Fbxo6a +  Fbxo32a + 
Fbxw9a +  Fbxl7 +  Fbxo7 +  Fbxo33 + 
Fbxw10 +  Fbxl8 +  Fbxo8 +  Fbxo34 + 
Fbxw11a +  Fbxl10 +  Fbxo9 +  Fbxo36 + 
Fbxw13  N/A Fbxl11 +  Fbxo10a +  Fbxo38 + 
Fbxw14  N/A Fbxl12 +  Fbxo11a +  Fbxo39 + 
Fbxw15  N/A Fbxl13a +  Fbxo15 +  Fbxo40b + +
Fbxw16  N/A Fbxl14 +  Fbxo16 +  Fbxo41 + 
Fbxw17  N/A Fbxl15 +  Fbxo17a +  Fbxo42 + 
Fbxw18  N/A Fbxl16 +  Fbxo18 +  Fbxo43 + 
Fbxw19  N/A Fbxl17 +  Fbxo20 -  (Obtained three
siRNAs from
QIAGEN.
None of them
can rescue IRS1
degradation)
Fbxo44a + 
Fbxw20
(Fbxw12)
+  Fbxl18a +  Fbxo21a +  Fbxo45 + 
Fbxl19 +  Fbxo22a +  Fbxo46a + 
Fbxl20 +  Fbxo24 +  Fbxo47a + 
Fbxl21  little
expression
in C2C12
myotubes
Fbxo48  N/A
Fbxl22 + 
aGenes were additionally tested by three individual siRNAs from QIAGEN. The knockdown efficiency was verified by qRT-PCR. The siRNAs targeting
Fbxw13-19, Fbxl21, Fbxo20, and Fbxo48 are not represented in the ubiquitin conjugation siRNA library from Dharmacon. The expression level of
Fbxl21 is low in C2C12 myotubes judged from qRT-PCR data. Three individual siRNAs targeting Fbxo20 were obtained from Qiagen. No inhibition
of IRS1 degradation is observed with knockdown of Fbxo20 to 40% of basal mRNA level.
b The only positive hit is Fbxo40.
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Fbxo40 Induces IRS1 Ubiquitination in MuscleIGF1 stimulation, can enhance ubiquitin conjugation, recombi-
nant His6-IRS1 preincubated with or without GST-IGF1RKD
was subjected to in vitro ubiquitination assay by immunoprecip-
itated SCFFbxo40 complex. Increased tyrosine phosphorylation
greatly enhanced polyubiquitination of IRS1 in vitro (Figure 4D).
Knockdown of Fbxo40 Results in Thicker Myotubes
We next sought to determine the in vivo consequences of
Fbxo40 knockdown, since IGF1 is capable of increasing the
size of postdifferentiated myotubes (Jacquemin et al., 2004;
Rommel et al., 2001; Semsarian et al., 1999). Based on the
knockdown efficiency of three siRNAs targeting Fbxo40 shown
in Figure 3A, we used the twomost effective siRNAs, siFbxo40_7
and siFbxo40_8, for this experiment. Since Fbxo40 expression
was detectable at later stages of differentiation (Figures 3D; Fig-
ure S5B), myotubes were transfected with siCON, siFbxo40_7,
and siFbxo40_8, 2 days postdifferentiation; then a day laterDevelopme(day 3 postdifferentiation), myotubes were treated with either
of two different doses of IGF1 for 24 hr. The diameter of myo-
tubes was measured using automated software, with ten
pictures of each treatment group. A representative picture of
myotubes postknockdown with siFbxo40_7 is presented in Fig-
ure 5A. The quantification of myotube diameter is shown in
Figure 5B. Among the siCON transfected groups, only 10 nM
IGF1 produced statistically significant thicker myotubes
compared with cells treated just with carrier; around 11%
increase in myotube diameter. However, introduction of
siFbxo40_7 results in significant thicker myotubes than siCON
transfected cells even without additional IGF1 treatment (Figures
5A and 5B). The effect seen is quite large—an approximately
50% increase in myotube diameter. It should be noted that my-
otubes produce endogenous IGF1 (data not shown). Larger
myotubes (approximately 20% increase in myotube diameter
compared with siCON transfected myotubes) were alsontal Cell 21, 835–847, November 15, 2011 ª2011 Elsevier Inc. 839
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Figure 3. Fbxo40 Targets IRS1 for Degradation in Proteosome
(A) C2C12 cells were transfectedwith three individual siRNAs to Fbxo40 or siCON 1day postdifferentiation. Forty-eight hours after transfection, cells were starved
and treated with carrier, IGF1 or IGF1 plus MG132 for 16 hr. Cell lysate was analyzed by western blotting. The quantification of the ratio of IRS1 to tubulin (mean ±
SD) was also indicated below graphs.
(B) C2C12 cells were transfected with siCON or siFbxo40_7 1 day postdifferentiation. Forty-eight hours after transfection, cells were starved and treated with
IGF1 plus Eme for 1, 2, 4, and 6 hr. Cell lysate was analyzed by western blotting. The quantifications are shown on the right.
(C) C2C12 myotubes transfected with siCON or siFbxo40_7 were treated with 1 or 10 nM IGF1. Cell lysate was analyzed by western blotting.
(D) Differentiating C2C12 cells were lysed with 1% NP-40 lysis buffer on each day of differentiation. Both the soluble and insoluble fractions (20 mg each sample)
were analyzed by western blotting. MyHC stands for myosin heavy chain. *The position of the specific band.
See also Figure S5.
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Fbxo40 Induces IRS1 Ubiquitination in Muscleobserved with siFbxo40_8, the less efficacious siRNA, after 1
and 10 nM IGF1 treatment (data not shown). Furthermore,
when IRS1 is knocked down (mRNA decreased to 65%of siCON
transfected cells, data not shown) together with Fbxo40, we saw
only an approximately 20% increase in myotube diameter (Fig-
ure 5C), which further demonstrated that Fbxo40 regulates my-
otube diameter through regulation of IRS1, as opposed to
some other potential substrate. Furthermore, larger myotubes
can also be observed after Fbxo40 knockdown in primarymouse
myotubes (Figure S5C).
We then checked whether Fbxo40 also regulates IRS1 protein
levels in mice. On day 0, mice tibialis anterior (TA) muscle was
electroporated with siCON in the left leg and siRbx1_1 or
siFbxo40_7 in the right leg. A pCMV-LacZ plasmid was840 Developmental Cell 21, 835–847, November 15, 2011 ª2011 Elscoinjected with siRNAs to help identify fibers with siRNA expres-
sion. After recovery for 2 days, IGF1 (100 mg per injection) was
injected intramuscularly into the TA muscle on the 2nd, 5th, and
7th day. Muscle was collected on the eighth day and protein
extracts were prepared. Figure 5D shows that IRS1 protein
was higher in siRbx1 and siFbxo40 electroporated samples
than siCON samples after IGF1 stimulation. With IGF1 treatment,
larger muscle fibers were observed with Fbxo40 knockdown:
18% ± 5% increase compared with siCON electroporated
contralateral legs (Figure 5E). Note that in Figure 5E, the fibers
without LacZ expression (marked with *) are of similar size in
siCON and siFbxo40_7 electroporated legs.
To determine the physiologic relevance of the data from myo-
tubes and to provide an alternate, perhaps more physiologicalevier Inc.
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Figure 4. Fbxo40 Associates with Skp1-cullin 1-Rbx1 and Ubiquitinates IRS1
(A) Day 3 C2C12 myotubes were treated with IGF1 and MG132 for 2 hr. Cell lysate (1 mg) was immunoprecipitated with 3 mg of anti-Fbxo40 antibody or
nonspecific IgG and sheep anti-rabbit IgG Dynabeads. An aliquot of the lysates was analyzed by western blotting along with 50% of the eluate. *The position of
the specific band.
(B) Time course of in vitro ubiquitination of recombinant His6-IRS1 by immunoprecipitated SCF
Fbxo40. All reactions were performed at 30C. One set of the
reaction was separated from the sheep anti-rabbit IgG Dynabeads, run on 4%–12% Bis-Tris gels, and immunoblotted with streptavidin-HRP (bottom panel). A
fraction (15%) of the elution from the beads was assayed by western blotting with anti-Fbxo40 antibody (middle panel). Another set of the reaction was subjected
to immunoprecipitation with anti-IRS1 antibody, run on 3%–8% Tris-Acetate gel, and immunoblotted with streptavidin-HRP (top panel). The bracket indicates
ubiquitinated IRS1. No E2 indicates that the reaction was carried out without UbcH5c. No Ubi indicates that the reaction was carried out without Biotin-N-terminal
ubiquitin. Mw of protein ladder in kDa is indicated on the left.
(C) Recombinant His6-IRS1 was incubated with GST-IGF1RKD at room temperature for 5, 10, 15, and 20 min. The reaction products were analyzed using
antiphospho-tyrosine (pY) antibody.
(D) Ubiquitination assay of recombinant His6-IRS1 preincubated with or without GST-IGF1RKD. Quantification of the polyubiquitinated His6-IRS1 was shown
under the blots (A.U.). *Densitometry cannot be accurately measured due to the overshadow from protein ladder on the left. An empty lane separating left and
right four lanes in the middle panel (IB:His) was deleted due to space constraint.
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Fbxo40 Induces IRS1 Ubiquitination in Musclemethod than electroporation, we generated mice with a global
deletion of Fbxo40. In the Fbxo40 knockout/LacZ knockin (KO)
mice, there is no detectable Fbxo40 mRNA and protein expres-
sion (Figures 6D and 6E). These KO mice are viable and have
a standard litter size. The female and male KO mice are signifi-
cantly heavier thanWT female andmale littermates, respectively,
from 4 to 9 weeks of age (Figure 6A), a growth phase associated
with enhanced IGF1 levels (Elis et al., 2010; Stratikopoulos et al.,
2008). To determine whether the increase in body weight seen in
the Fbxo40 nulls is due to changes inmuscle mass, at 6 weeks of
age, TA, extensor digitorum longus (EDL), quadriceps femoris
(Quad), triceps brachii (Tri), soleus (Sol), plantaris (PLA), gastroc-Developmenemius (GA)muscles and heart were dissected out andweighed;
TA, EDL, and PLA muscles of the Fbxo40 KO mice are signifi-
cantly heavier than WT mice (n = 33 for KO mice and n = 20 for
WTmice, p < 0.05 by one-way ANOVA) (Figure 6B). Consistently,
the frequency distribution of fiber cross-sectional area (CSA) of
Type I, IIA and IIB muscle fibers shifted to the right in KO mice
compared with WT controls (Figure 6C). Fbxo40 KO mice also
demonstrate greater IRS1 protein levels in the TA muscle
compared with WT mice (Figure 6D), while IRS1 mRNA levels
are similar between WT and KO mice (Figure 6E). Therefore,
endogenous levels of Fbxo40 are required to regulate IRS1
and resultant growth rates and muscle mass in young animals.ntal Cell 21, 835–847, November 15, 2011 ª2011 Elsevier Inc. 841
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Figure 5. Knockdown of Fbxo40 Induces Hypertrophy in Skeletal Myofibers
(A) C2C12 cells were transfected with siCON or siRNAs targeting Fbxo40 2 days postdifferentiation. Twenty-four hours posttransfection, cells were treated with
carrier, 1 or 10 nM IGF1 for additional 24 hours, and then fixed with 5% glutaraldehyde for imaging. Ten pictures were taken for each condition. A representative
picture is shown for each condition.
(B) Myotube diameters were determined from ten pictures for each treatment of the experiment shown in Figure 6A using automated software. The value of every
other treatment was normalized to themean value of siCON transfected and carrier treated cells (siCON []). The relativemean fold change ± SEMwas calculated
and plotted. #p = 0.0002 versus carrier-treated cells in siCON transfected group by one-way ANOVA and Bonferroni post test, n = 10. *p < 0.0001 versus siCON
transfected group by two-way ANOVA and Bonferroni post test, n = 10.
(C) Two days postdifferentiation, C2C12 cells were transfected with (1) siCON+siFbxo40_7; (2) siCON+siIRS1 (Dharmacon); (3) siFbxo40_7+siIRS1. Twenty-four
hours posttransfection, cells were fixed with 5% glutaraldehyde for imaging. The value of every other treatment was normalized to the mean value of
(siCON+siIRS1) transfected cells. The relative mean fold change ± SEM was calculated and plotted. *0.01 < p < 0.05 (siCON+siFbxo40_7) versus
(siFbxo40_7+siIRS1) by one-way ANOVA and Bonferroni post test, n = 10. In addition, for the pair of (siCON+siFbxo40_7) versus (siCON+siIRS1), p < 0.0001 by
one-way ANOVA and Bonferroni post test, n = 10. For the pair of (siCON+siIRS1) versus (siFbxo40_7+siIRS1), 0.01 < p < 0.05 by one-way ANOVA and Bonferroni
post test, n = 10.
(D) siCON and siRbx1_1 (left panels) or siFbxo40_7 (right panels) were electroporated into left and right TA muscles, respectively. IGF1 was injected intra-
muscularly and protein lysate was analyzed by western blotting. The quantification of densitometry can be found in the table below the blots for the siFbxo40
electroporated samples. For each mouse, the protein level in siFbxo40 electroporated leg was normalized against siCON electroporated leg. *The position of the
specific band.
(E) siCON and siFbxo40_7 were electroporated into left and right TA muscles, respectively. IGF1 was injected intramuscularly. Serial transverse sections, 8 mm
thick, were cryosectioned and stained for LacZ. A representative image was shown on the left panels. The cross-sectional area (CSA) of LacZ positive fibers from
three mice was measured using Adobe Photoshop. The mean CSA value of siFbxo40_7 electroporated leg was normalized to that of siCON electroporated
contralateral leg. The relative mean fold change ± SD was calculated and plotted on the right panel. *Fibers that have no LacZ expression.
See also Figure S5.
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Figure 6. Knockout of Fbxo40 Enhances Muscle Mass
(A) Body weights of Fbxo40 KO and WT mice were measured twice per week from age of 4–9 weeks. *p < 0.0001 KO versus WT male mice and #p < 0.0001 KO
versus WT female mice by two-way ANOVA (age3 genotype) and Bonferroni post test (either gender was analyzed separately; n = 26 for KO females and n = 22
for WT females; n = 19 for KO males and n = 15 for WT males).
(B) TA, extensor digitorum longus (EDL), quadriceps femoris (Quad), triceps brachii (Tri), soleus (Sol), plantaris (PLA), and gastrocnemius (GA) muscles from both
legs were isolated from 6-week-old Fbxo40 KOmice andWT littermates. The average wet weight of left and right of eachmuscle was compared between KO and
WT mice. Mean weight change ± SEM of KO mice compared with WT controls were plotted. *p < 0.05 versus WT mice by one-way ANOVA and Bonferroni post
test, n = 33 for KO mice and n = 20 for WT mice.
(C) Cryosections were prepared from the soleus, plantaris, and gastrocnemius muscles of both Fbxo40 KO andWTmice (n = 5 for each genotype). The frequency
distribution of the CSA for fibers immunostained positive for MyHC type I, IIA, and IIB were quantified.
(D) Protein lysates were prepared from TA muscles of Fbxo40 KO and WT mice (24 weeks old) and analyzed by western blotting. eIF4E was used as loading
control. The quantification of the ratio of IRS1 to eIF4E (mean ± SD) is also indicated below the graphs.
(E) RNA was isolated from TAmuscles of Fbxo40 KO andWTmice (24 weeks old) and analyzed by qRT-PCR. The geometric mean of TBP, Dnttip2, TMEM1, and
Vps26a expression levels was used as internal control to normalize the RNA amount added. The mean fold change ± SEM of three independent samples is
plotted. *p < 0.0001 versus WT mice by one-way ANOVA and Bonferroni post test, n = 3.
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Fbxo40 Induces IRS1 Ubiquitination in MuscleDISCUSSION
IGF1 is an anabolic growth factor for skeletal muscle—for
example, it causes significant hypertrophy when transgenically
overexpressed (Coleman, et al., 1995; Musaro` et al., 2001). The
particular signaling pathway that mediates IGF1-induced hyper-
trophy is the IGF1R/IRS1/PI3K/Akt pathway, illustrated by the
finding that overexpression of activated Akt in skeletal muscle
recapitulates the hypertrophic phenotype (Rommel et al., 2001;
Pallafacchina, et al., 2002; Lai et al., 2004). However, the timeDevelopmecourse of Akt activation after IGF1 stimulation is limited, suggest-
ing the existence of regulatory steps that control the extent and
degree of IGF1-induced signaling. While transgenic expression
of IGF1 in muscle results in enhanced muscle size, this increase
in mass is limited to 2-fold, despite the continued availability of
IGF1 (Colemanet al., 1995). This is in contrast to themuchgreater
hypertrophy that can be achieved by activating the pathway
downstream of IRS1, as was seen using a constitutively active
Akt for just 2 weeks, which results in a several-fold increase in
skeletal muscle size (Lai et al., 2004; Izumiya et al., 2008).ntal Cell 21, 835–847, November 15, 2011 ª2011 Elsevier Inc. 843
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Fbxo40 Induces IRS1 Ubiquitination in MuscleIn this study, we found that IRS1 is rapidly degraded in
myotubes upon IGF1 stimulation, and that this occurs via the
ubiquitin-proteasome pathway. A search for the responsible E3
ligase quickly became focused on a particular multicomponent
family of E3 ligases—the SCF family (for Skp1, cullin 1,
F-box)—since each of its components, along with Rbx1 (the re-
quired RING-finger member of this complex) were demonstrated
to be necessary for IRS1 degradation. For the SCF complex E3s,
substrate specificity is mediated by the protein that contains the
F-box domain. In mice, there are over 70 genes encoding F-box-
containing proteins, and we screened almost the entire set to
find the responsible gene. This screen resulted in a single hit—
Fbxo40.
Several other studies have reported E3 ligases that can target
IRS1 for proteasomal degradation—IRS1 was recently identified
as a proteolytic target of the cullin 7-Fbxw8 E3 ligase complex,
a process that required active mTOR/p70S6K phosphorylation
(Xu et al., 2008). In the prior reports, turnover of IRS1 was not
restricted to differentiated muscle cells, nor did it occur rapidly
after activation by IGF1 stimulation. In the present study, IRS1
was rapidly degraded only in differentiated skeletal myotubes
upon treatment with IGF1, and this turnover seemed to only
require direct signaling from IGF1R, since modulating the path-
ways downstream of IRS1 did not perturb the effect. None of
these previously identified E3s regulated the IGF1-mediated
degradation of IRS1 in skeletal myotubes (Figures S3A–S3D,
S3F, and S3G and data not shown). Furthermore, both the cullin
7-Fbxw8 complex and Cbl-b failed to target IRS1 in C2C12
myoblasts in response to IGF1 (Figures S3E and S3H).
Fbxo40 is muscle specific, being expressed at appreciable
levels only in skeletal muscle and heart. Its expression also
increases upon differentiation ofmuscle cells, whichmay explain
why it was not identified before, and why the rapid effects it
mediates are only seen in this particular cell type. We were
able to reproduce prior reports of more gradual IRS1 turnover
when studying undifferentiated myoblasts, where Fbxo40 is
not detectable. When Fbxo40 is knocked down in C2C12
myotubes, IRS1 half-life increases to more than 6 hr, the similar
slow rate observed in myoblasts (Figure 3B; Figure S2A). Since
undifferentiated myoblasts do not express appreciable levels
of Fbxo40, we overexpressed Fbxo40 in C2C12 myoblasts,
resulting in a faster degradation of IRS1 upon IGF1 treatment
(Figure S5D). Thus Fbxo40 is necessary and sufficient to cause
IGF1-dependent IRS1 degradation in skeletal muscle cells.
Fbxo40 directly induces IRS1 ubiquitination in biochemical
assays, proving that it is a direct mediator of IRS1 turnover.
Phosphorylation of IRS1 by IGF1R further stimulated ubiquitin
conjugation, consistent with the observation that IRS1 must be
phosphorylated by IGF1R first, and only then is targeted for
degradation by the proteasome. The vast majority of SCF E3
ligase substrates are targeted only after post-translational
modification – usually phosphorylation.
The phenotypic consequence of knocking down Fbxo40 in
C2C12 myotubes is quite dramatic. We tested this plus and
minus IGF1 stimulation, asking if a decrease in Fbxo40 expres-
sion would enhance IGF1-mediated hypertrophy. Knockdown
of Fbxo40 was sufficient to cause a 50% increase in myotube
size. However, it should be noted that myotubes produce
endogenous IGF1, which are released into the cell culture844 Developmental Cell 21, 835–847, November 15, 2011 ª2011 Elsmedium; therefore, the implication is that the decrease in
Fbxo40 results in an uncontrolled autocrine-mediated hypertro-
phic response to endogenously-produced growth factor, helping
to explain why Fbxo40 is necessary to regulate this autocrine
signaling through control of IRS1 levels. Furthermore, hyper-
trophy can also be observed in primary mouse myotubes after
knocking down Fbxo40 by either of two different siRNAs.
In the presence of IGF1, knockdown of Fbxo40 resulted in
significantly larger muscle fibers in adult animals. Adult Fbxo40
null animals have significantly more IRS1 protein in their skeletal
muscle, demonstrating that Fbxo40 is required to regulate IRS1
levels in vivo (Figure 6D). We examined the animals during their
early growth phase, because this is the phase that is associated
with higher IGF1 levels, as a result of growth hormone (Elis et al.,
2010; Stratikopoulos et al., 2008). During this growth phase,
Fbxo40 nulls demonstrated statistically significant increases in
size in comparison to their wild-type littermates. Muscle mass
in the Fbxo40 KO mice was analyzed at 6 weeks of age, and
compared with WT littermates and a statistically significant
increase was observed in themass of TA, EDL, and PLAmuscles
in the null animals.
The rapid proteolysis of IRS1 upon IGF1 stimulation, requiring
new protein synthesis and subsequent replacement of IRS1 to
allow for further signaling, suggests a useful evolutionary regula-
tion of IGF1 signaling. Skeletal muscle ceases to be permissive
for IGF1-induced increases in mass unless protein synthesis
pathways are active, which happens in conditions where the
animal is fed. In settings where protein synthesis cannot occur,
IRS1 cannot be regenerated, thus turning off IGF1-induced
signaling in skeletal muscle. Also, Fbxo40 is apparently neces-
sary to control autocrine signaling, since in myotubes, where
IGF1 is produced, hypertrophy is enhanced when Fbxo40 is
downregulated. Such autocrine expression of IGF1 has been
reported in animals and humans upon anabolic exercise—so
presumably there is a role for Fbxo40 in controlling the amount
of hypertrophy in such settings.
This study thus identifies a key regulatory node for IGF1
signaling in muscle and identifies Fbxo40 as a potential target
for positively modulating the efficacy of IGF1 as a treatment
modality.EXPERIMENTAL PROCEDURES
Antibodies and Inhibitors and siRNA
Sequences used in this study can be found in Supplemental Experimental
Procedures.
Inhibitors Treatment and Western Blotting
Cells were starved in serum free DMEM for 4 hr with an exchange of fresh
medium at 2 hr. Then, the signaling inhibitors were added to pretreat cells
for 30 min before incubation with freshly prepared inhibitors with 10 nM
IGF1 (the R3 long form, Sigma, St. Louis, MO) or 10 mM Emetin (Sigma,
St. Louis, MO) or 20 mMMG132 (Alexis Biochemicals, Carlsbad, CA) as spec-
ified for an additional 5 hr. Cells were rinsed two times with PBS and harvested
in ice-cold RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS [pH 7.4]) with 10 mM MG132 and protease/
phosphatase inhibitors tablets (Roche, Basel, Switzerland). Cell lysates were
rotated at 4C for at least 1 hr and spun for 10 min at 16,000 3 g in a micro
centrifuge at 4C. Protein concentrations of the supernatants were determined
byBCAProtein Assay Kit (Pierce/Thermo Fisher Scientific, Rockford, IL). Equal
amounts of proteins (20 mg) were loaded per lane on 4%–12% Bis-Tris gelsevier Inc.
Developmental Cell
Fbxo40 Induces IRS1 Ubiquitination in Muscle(Invitrogen, Carlsbad, CA) and transferred onto PVDF membranes (Millipore,
Billerica, MA). Immunoreactivity was detected by ECL and exposed to
film or Kodak Image Station 4000R (Eastman Kodak Company, Rochester,
NY). Densitometry was analyzed using Kodak Molecular Imaging software,
version 4.0.
In Figure 3D, cell lysates were separated into 1% NP-40 soluble and
insoluble fractions as described previously (Clarke et al., 2007). Equal amounts
of protein were analyzed by western blotting.
Measurement of Protein Stability
Cells were starved in serum free DMEM for 4 hr with an exchange of fresh
medium at 2 hr. At time zero, 10 mM Eme, or 100 mg/ml of CHX, along with
10 nM IGF1 and 20 mM MG132 were added to cells as specified. At the
indicated time intervals, cells were rinsed twice with PBS and harvested
in ice-cold RIPA buffer with 10 mM MG132 and protease/phosphatase inhibi-
tors. Cell lysates were rotated at 4C for at least 1 hr and spun for 10 min at
16,000 3 g in a microcentrifuge at 4C. The supernatants were analyzed by
western blotting.
In Vivo Ubiquitination Assay and Immunoprecipitation
A his-myc-ubiquitin adenoviral expression construct was sent to Welgen Inc.
(Worcester, MA) for production and purification. Purified adenovirus was
added to C2C12 cells 2 days postdifferentiation at a concentration of 2 3
108 pfu/ml for overnight. Forty-eight hours after infection, cells were starved
and treated with 10 nM IGF1, 20 mM MG132, and 5 mM G5 (an isopeptidase
inhibitor, EMDChemicals, Inc., Gibbstown, NJ) as specified for 5 hr. Then cells
were rinsed two times with PBS and harvested in 800 ml ice-cold RIPA buffer
supplemented with 10 mMMG132, 5 mMG5 and protease/phosphatase inhib-
itors per 10 cm dish. Cell lysates were rotated at 4C for at least 1 hr, and spun
for 10min at 16,0003 g in a microcentrifuge at 4C. This material (1 mg of total
protein) was diluted with Triton lysis buffer (50 mM Tris-HCl, 150 mM NaCl,
5 mM EDTA, and 1% Triton [pH 7.4]) and incubated with the rabbit polyclonal
IRS1 antibody (Cell Signaling, Denvers, MA) and nonspecific rabbit IgG (each
3 mg) along with 40 ml of M-280 sheep anti-rabbit IgG Dynabeads (Invitrogen,
Carlsbad, CA) for overnight at 4C with rotating. The beads were then washed
three times with Triton lysis buffer. Elution was carried out by resuspending
beads in 30 ml of sample buffer with 100 mM DTT, then boiling at 95C for
5 min. An aliquot (20 mg) of the lysate before immunoprecipitation were
analyzed by western blotting along with 100% of the eluate.
In the IRS1 and Rbx1 coimmunoprecipitation experiment (Figure 2E), cell
lysate (1 mg) were incubated with the rabbit polyclonal IRS1 antibody (Cell
Signaling) and nonspecific rabbit IgG (each 3 mg) along with 40 ml of M-280
sheep anti-rabbit IgG Dynabeads for overnight at 4Cwith rotating. The bound
proteins were eluted with 30 ml of sample buffer with 100 mM DTT.
Alternatively, in the experiment shown in Figure 4A, day 3 C2C12 myotubes
were treated with 10 nM IGF1 and 20 mM MG132 for 2 hr. Cell lysate (1 mg)
were incubated with Fbxo40 antibody and nonspecific rabbit IgG (3 mg each)
along with 40 ml of M-280 sheep anti-rabbit IgG Dynabeads.
In Vitro Kinase Reaction
Purified GST-IGF1RKD was purchased from Enzo Life Sciences (Plymouth
Meeting, PA). Recombinant N-terminal His6 tagged rat IRS1 (protein
expressed and purified from Sf9 cells) was purchase from Millipore (Billerica,
MA). His6-IRS1 (0.1 mg, 0.56 pmol) was incubated with GST-IGF1RKD (1 mg,
14 pmol) in the reaction buffer (250 mM Tris [pH 7.5], 2 mM ATP-Mg, 25 mM
MnCl2, 5mMDTT, and 5mg/ml BSA) in a total volume of 50 ml at room temper-
ature for the specified time.
In Vitro Ubiquitination Assay
For the in vitro ubiquitination assay, yeast E1, human recombinant UbcH5c,
human Biotin-N-terminal Ubiquitin, Ubiquitin Aldehyde, and Energy
Regeration Solution (ERS) were purchased form Boston Biochem, Inc. (Cam-
bridge, MA). Lactacystin were purchased from Enzo Life Sciences (Plymouth
Meeting, PA).
Day 2 C2C12 myotubes were treated with 10 nM IGF1 and 20 mMMG132 in
complete medium for 16 hr. Cell lysate (1mg) were incubated with anti-Fbxo40
antibody or nonspecific rabbit IgG (each 3 mg) along with 40 ml of M-280 sheep
anti-rabbit IgG Dynabeads for overnight at 4C with rotating. In one controlDevelopmecondition, lysate without any IgG was incubated with the beads. The beads
were then washed three times with Triton lysis buffer for 10 min with rocking.
The ubiquitination reactions were carried out by addition of E1 (125 nM),
E2 (UbcH5c, 3.125 mM), Biotin-N-terminal ubiquitin (5.4 mM), 13 ERS,
Ubiquitin Aldehyde (5 mM), Lactcystin (20 mM), recombinant His6-IRS1
(40 ng, 0.22 pmol), and reaction buffer (50 mM HEPES, 0.6 mM DTT
[pH 7.4]) in a total volume of 40 ml to the beads. Reactions were carried out
at 30C for 0, 30, 60, 90 min. Control reactions were carried out with the
omission of E1, or E2 (UbcH5c), or Biotin-N-terminal ubiquitin, or His6-IRS1
at 30C for 90 min. Each condition was carried out in duplicate sets. For one
set, reactions were ended by separating the reaction mix from the beads,
adding SDS-PAGE sample buffer, and heating. Reaction mixtures were run
on 4%–12% Bis-Tris gels with MOPS running buffer and blotted with strepta-
vidin-conjugated horseradish peroxidase (Pierce). Proteins bound to the
beads were eluted with 35 ml of sample buffer with 100 mM DTT, run on
4%–12% Bis-Tris gels with MOPS running buffer and blotted with a rabbit
polyclonal antibody against Fbxo40. For another set, additional ice-cold Triton
lysis buffer (800 ml) was added to stop the reaction. Then reaction mixtures
were separated from the beads and subjected to another round of
immunoprecipitation with rabbit polyclonal anti-IRS1 antibody (Cell Signaling).
The bound proteins were eluted with 35 ml of sample buffer with 100 mM DTT
and separated on 3%–8% Tris-Acetate gels (Invitrogen) and transferred to
PVDF membranes for immunoblotting with streptavidin-conjugated horse-
radish peroxidase.
Alternatively, in Figure 4D, recombinant His6-IRS1 was preincubated with or
without GST-IGF1RKD for 25 min at room temperature. Then the two sets of
His6-IRS1 (0.18 pmol/reaction) were added to full ubiquitination reactions as
described above. The reactions were carried out at 30C for 0, 30, 60, and
90 min.
RNAi
To screen for the F-box protein, day 1 C2C12 cells grown in 12-well plates
were transfected with Dharmacon siRNA library (100 mM stock solution) or
siCON using Dharmafect 3 according to the protocol described by Dharma-
con. The final concentration of siRNAs incubated with cells is 100 nM. Forty-
eight hours after transfection, cells were starved for 4 hr in serum free
DMEM and treated with 10 nM IGF1 or 20 mM MG132 for 16 hr at 37C. Cells
were lysed and proteins were analyzed by western blotting. RNA expression
was checked by qRT-PCR 48 hours posttransfection.
For validation experiment, we further optimized siRNA transfection protocol
to achieve better knockdown. One day postdifferentiation, C2C12 cells grown
in 6-well plate were transfected with siRNAs from QIAGEN using Dharmafect
1. For each well, two transfection mixes were prepared. For mix 1, 98 ml of
OPTI-MEM was combined with 2 ml of Dharmafect 1 and incubated for 5 min
at room temperature. For mix 2, 2 ml of siRNA (10 mM stock) was diluted in
98 ml of OPTI-MEM. Mix 1 and mix 2 were then combined and incubated at
room temperature for 20 min. Cells were fed with fresh 800 ml of antibiotic-
free differentiation medium per well. The transfection mixture was added
drop-wise onto the cells.
In Figures 5A–5C, C2C12 cells grown in 6-well plate were transfected with
siCON, siFbxo40_7, and siFbxo40_8 from QIAGEN using Dharmafect 1,
2 days postdifferentiation. Twenty-four hours after transfection, cells were
treated with carrier, 1 or 10 nM IGF1 for additional 24 hours at 37C. Cell
morphology was monitored every hour by IncuCyte Live Cell Imaging system
(Essen BioScience, Ann Arbor, MI) during this period. At the end of the
treatment, cells were washed and fixed with 5% Glutaraldehyde for myotube
diameter measurement (see below for details).
Measurement of Myotube Diameter
Cells were fixed with 5%Glutaraldehyde at 37C for 30 min. Ten pictures were
taken for each condition with 10-fold magnification lens using a Carl Zeiss Axio
Observer.Z1 fluorescent microscope (Carl Zeiss). Myotube diameters were
determined from TIFF format pictures using automated software developed
by Novartis.
Mice Procedures
C57BL/6NTac mice (Taconic) at 12 weeks of age were used for electropora-
tion. On day 0, 50 mg of pCMV-LacZ plasmid was coinjected with 500 pmolntal Cell 21, 835–847, November 15, 2011 ª2011 Elsevier Inc. 845
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injection, limbs were pulsed with five ‘‘positive’’ pulses of 125 V/cm, 30 ms
duration, with 400 ms interval time followed by five ‘‘negative’’ pulses of the
same parameter. Long-R3-IGF1 (100 mg per injection) was injected intramus-
cularly into the TAmuscle on the 2nd, 5th, and 7th day. On the 8th day, mice were
sacrificed and TA muscle was rapidly dissected and snap frozen in 2-methyl-
butane pre-cooled in liquid nitrogen. Serial transverse sections, 8 mm thick,
were cryosectioned and subbed to positively charged slides. Sections were
stained for b-galactosidase (LacZ). Images of the entire tissue section were
acquired using Scanscope (Aperio, Vista, CA) and the cross-sectional area
(CSA) of LacZ positive fibers was measured using Adobe Photoshop. The
rest of TA muscle was pulverized under liquid nitrogen and protein was
extracted.
A construct containing a 3.2 kb 50 and a 5.8 kb 30 homology arms were used
to replace exon 2 and part of exon 3 of the Fbxo40 gene (transcript ID:
ENSMUST00000075869 in ENSEMBL) with LacZ cDNA and a neomycin
selection cassette via homologous recombination in ES cells. Chimera mice
were obtained by injecting ES cell clone via standard procedures. Absence
of Fbxo40 gene expression was verified by qRT_PCR and western blotting.
For Figure 6C, serial sections, 8 mm thick, were cut from the frozen right
soleus, plantaris, and gastrocnemius muscles and coimmunostained for
laminin and MyHC type I or type IIA or type IIB to determine fiber type compo-
sition and fiber cross-sectional area as describe before (Ibebunjo et al., 2011).
Images of the entire tissue section were acquired using Scanscope (Aperio,
Vista, CA). The frequency distribution of the CSA of all fibers in the section
was determined automatically using a custom software, Astoria version 3.0,
developed at Novartis Institutes for Biomedical Research. More than 3,500
fibers in each section were measured automatically by this method.
All animal procedures were approved by the Institutional Animal Care and
Use Committee of Novartis Institute for Biomedical Research and were in
compliance with the Animal Welfare Act Regulations 9 CFR Parts 1, 2, and
3, and US regulations (Guidelines for the Care and Use of Laboratory Animals,
1995).Statistical Analyses
Except in Figures 5B and 6A, differences between treatments were analyzed
using one-way ANOVA and Bonferroni post test.
In Figure 5B, differences between different siRNA transfected groups were
analyzed using two-way ANOVA. Significance was determined by Bonferroni
post test. Values were considered significant at p < 0.01. Within siCON or
siFbxo40_7 transfected groups, differences between carrier, 1 and 10 nM
IGF1-treated cells were analyzed using one-way ANOVA and Bonferroni
post test. Values were considered significant at p < 0.01.
In Figure 6A, mean body weight data between KO and WT mice (either
gender separately) were analyzed using two-way ANOVA (age 3 genotype).
Significance between genotype of both genders was determined to be p <
0.0001 by Bonferroni post test.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experimen-
tal Procedures and can be found online at doi:10.1016/j.devcel.2011.09.011.ACKNOWLEDGMENTS
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